Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CK-3773274 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| CK-3773274 for Single Ascending Dose (SAD) Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274 |
| Placebo comparator for SAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator |
| CK-3773274 for Multiple Dose (MD) Cohort | EXPERIMENTAL | Subjects will receive multiple doses of CK-3773274 |
| Placebo comparator for MD Cohort | PLACEBO_COMPARATOR | Subjects will receive multiple doses of placebo comparator |
| Name | Type | Description |
|---|---|---|
| CK-3773274 | DRUG | CK-3773274- Tablets |
| Placebo | DRUG | Placebo- Tablets |
Inclusion Criteria: 1. Healthy Chinese males and females between 18 and 45 years of age, inclusive 2. Body weight ≥50kg and body mass index (BMI) within 18 to 26 kg/m2, inclusive 3. Acoustic windows adequate for accurate transthoracic echocardiograms 4. Normal cardiac structure and function, as det...
CK-3773274 is an investigational small molecule being developed for obstructive hypertrophic cardiomyopathy, a cardiovascular condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and pharmacokinetics in patients with this condition and in healthy subjects.
CK-3773274 is being developed by Milestone Pharmaceuticals Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol MIST. The company is conducting clinical research on this investigational drug for the treatment of obstructive hypertrophic cardiomyopathy.
CK-3773274 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies for commercial use. The drug is being studied in early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in humans.
CK-3773274 has one completed Phase 1 clinical trial registered under NCT04783766. This study evaluated the safety, tolerability, and pharmacokinetics of the drug in patients with obstructive hypertrophic cardiomyopathy and in healthy adult subjects. The trial was conducted in China and enrolled 28 participants.
CK-3773274 is a unique investigational compound developed by Milestone Pharmaceuticals. No alternative names for this drug have been disclosed in the available clinical trial information. It is being studied specifically for obstructive hypertrophic cardiomyopathy and is not known to be marketed under any other name.